ARTHUR-D.-LITTLE
Arthur D. Little (ADL) today announced that it has been awarded multiple high impact projects by the European Space Agency (ESA) to help identify the most promising services for next generation satellite communication (SatCom) infrastructure. ADL will conduct a major consultation process with key members of the transport, energy, infrastructure and media industries, plus stakeholders in law enforcement and emergency services, to identify and assess potential applications and services that could be delivered via satellite in the next decade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005719/en/
ADL will be responsible for four studies in total. Three of the studies are part of the Advanced Research in Telecommunications Systems (ARTES) 4.0 Strategic Programme Line “Space Systems for Safety and Security” (4S), and are supported by the Italian Space Agency:
- Safety of Future Transport
- Safeguarding Essential Services
- Satellite Applications for Public Safety
As part of its ‘Open Consulting’ approach, ADL will conduct these studies with input from Distretto Tecnologico Aerospaziale (DTA).
The fourth study is an ARTES4.0 Business Applications Feasibility Study and is supported by the Norwegian Space Agency:
- Port of the Future
ADL will conduct this study in collaboration with Marlink and CLS.
With society and the economy dependent on telecommunications networks, the aim of 4S is to support the development of secure SatCom systems to both improve digital infrastructure resilience across Europe and the rest of the world, and provide innovative services and solutions. As terrestrial networks become increasingly vulnerable to disruption and attack, integrating next generation SatCom systems with the existing digital infrastructure can help make these networks more resilient and secure.
The Safety of Future Transport study will focus on how next generation SatCom solutions can increase safety and efficiency in the fast-evolving aviation, maritime and railway sectors, with potential applications relating to unmanned aircraft and ships, and automated traffic management systems. Safeguarding Essential Services will focus on how SatCom can help protect critical infrastructure such as energy utilities as well as public media. Satellite Applications for Public Safety will focus on how SatCom can supplement and support existing Public Protection and Disaster Relief (PPDR) networks used by first responders such as the police, fire brigade, health services and search & rescue.
The Port of the Future study will assess the technical feasibility and economic viability of new Earth observation and SatCom-based services for the port industry, focusing not only on operations of the port itself, but also on monitoring their environmental impact in terms of air and water quality.
Francesco Marsella, Managing Partner and Global S&O Practice Leader at ADL , comments: "SatCom has an increasingly vital role to play in protecting our society and making its infrastructure more secure and resilient. As terrestrial networks become more prone to failure, whether due to natural disaster or cyberattack, SatComs can support and maintain European telecoms systems. These studies will be key to developing existing satellite systems and identifying the services of the future.”
Lars Thurmann-Moe, Managing Partner, ADL Norway , comments: “It is not always appreciated quite how important the maritime sector remains, with the great majority of goods still transported by sea. SatCom is already central to modern maritime operations in terms of communication and navigation, but there is still so much more that can be done to improve these operations, and also reduce the industry’s environmental footprint – for instance, helping to quickly pinpoint oil spillages.”
Matteo Ainardi, Head of the Aerospace & Defense Competence Center at ADL , comments: "The satellite industry is today being disrupted by the introduction of new technologies such as large scale low earth orbit (LEO) constellations, reusable launchers and phased-array antennas. It is the right time to assess the evolving demand for SatCom solutions, and develop a next generation SatCom capability that can leverage these major technological breakthroughs to the benefit of the European society and economy. ADL is highly involved in the commercial space sector – as such, we are very pleased to be working with ESA on these studies, and look forward to applying our industry expertise to help define the SatCom-based services and applications of the future.”
To find out more about Arthur D. Little’s work in the space industry, please visit www.adlittle.com/en/industries/aerospace-defense
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005719/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
